Natural Alternatives International is a Carlsbad contract manufacturer whose shipments are rising again while the factory still cannot cover its own overhead, and that gap is the entire equity story. Sales reached $36 million in the fiscal third quarter. The net loss still widened to $4 million. Volume came from private-label work for a handful of direct-selling brands, yet cash from operations stayed negative and working capital kept shrinking. After the first quarter, management told investors the second half of the year would restore profit. By mid-winter that claim was withdrawn after several multi-level marketing clients cut forecasts and delayed launches. The market now prices the common equity as a thin residual claim on a real-estate-heavy balance sheet rather than as a going manufacturing franchise.
The tension sits in the two engines. Private-label contract manufacturing is almost the entire revenue base and is growing because one large customer and a cluster of newer accounts are shipping more product. Patent and trademark licensing around CarnoSyn beta-alanine, the clinically studied performance amino acid the company has spent decades defending, is the higher-margin stream and it is shrinking. Nine-month sales reached $108 million. Licensing slipped to $5 million. TriBsyn and CarnoSyn 4X were built to remove the tingling side effect that kept beta-alanine out of wellness and ready-to-drink formats, but those products have not yet replaced lost royalty and raw-material orders. A reader who only watches the top line would think the turn is underway. A reader who watches gross profit and cash would conclude the opposite.
The quarter also forced a capital-structure change. Wells Fargo had already cut the revolver the prior summer. Legacy Corporate Lending then replaced both the working-capital line and the powder-plant term loan, pairing a $20 million revolver with an $11 million real-estate note. The quarterly report arrived a day late because that refinance was still closing. The initial real-estate coupon sits well above a conventional bank mortgage, and a domestic fixed-charge coverage test begins in the autumn. The forward question is whether factory absorption, the Juice Plus+ franchise, and the new CarnoSyn formats can produce enough cash to live with a specialty lender, or whether the equity remains a cheap option on buildings.